KRAS and non-small cell lung carcinoma: <h4>Purpose</h4>To evaluate the cost-effectiveness of sotorasib versus docetaxel in non-small cell lung cancer (NSCLC) patients with KRAS<sup>G12C</sup> mutation from the China and United States'social perspective.<h4>Materials and methods</h4>A Markov model that included three states (progression-free survival, post-progression survival, and death) was developed.